• The Bing Center for Waldenström's Macroglobulinemia

    Dana-Farber/Brigham and Women's Cancer Care

    The Bing Center for Waldenström's Macroglobulinemia provides care and new therapies through clinical trials to patients with Waldenström's macroglobulinemia and related Immunoglobulin M (IgM) disorders.

    About the Center

    The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:

     

    The Treatment Team

    The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.

    Waldenström's Macroglobulinemia Leadership

    Steven P. Treon, MD, PhD, Director, Bing Center for Waldenström’s Macroglobulinemia

    Waldenström's Macroglobulinemia Physician

    Jorge J. Castillo, MD 

    Waldenström's Macroglobulinemia Nursing Team

    Stacey Chuma, RN
    Sandra Kanan, ARNP

    Clinical Research

    Each patient's care combines the finest treatments currently available for Waldenström's macroglobulinemia with innovative new therapies based on research discovered through the collaboration of the center's laboratories and many other scientists from around the world.

    The Bing Center for Waldenström's Macroglobulinemia offers patients access to a wide range of clinical research trials. The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to swiftly and efficiently take discoveries made in the laboratory to the clinic where they can benefit the health and well-being of the patient.

    This include studies aimed at improving the outcomes of patients undergoing biological therapies using agents in trials such as Rituxan and bortezomib that attempt to kill Waldenström's macroglobulinemia tumor cells directly. The center also has clinical research trials evaluating supportive therapies like statins and phosphodiesterase inhibitors to help understand the mechanics of the disease.

    Contact Us

    New Patients

    Waldenström's Macroglobulinemia: 617-632-3823 or 617-632-5138, or use this online form to make an appointment.

    Current Patients

    Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.

    Fax

    617-632-3730 

    Mailing address

    Hematologic Malignancies Division
    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

     
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Make an Appointment

    • New adult Waldenström's Macroglobulinemia patients:
      617-632-3823 or 617-632-5138 
    • Or complete the online form.
     
  • Highest ranked in New England

  • Waldenström's online community

    • Join the Dana-Farber Waldenström's Macroglobulinemia community on CancerConnect for support and information from others affected by this disease.